



Suven Life Sciences presenting Pre-clinical and Clinical data of NCEs at Neuroscience (SFN) 2022

Hyderabad, India (November 11, 2022): Suven Life Sciences Ltd (Suven) announced several poster presentations covering positive Pre-clinical and Clinical data of advanced clinical candidates and research molecules from their portfolio of new chemical entities (NCEs) at Neuroscience (SFN) 2022 hybrid conference, to be held in San Diego, California and virtually during 12-16, November 12-16, 2022. Neuroscience 2022 is the annual meeting of the Society for Neuroscience (SfN) and around thirty thousand neuroscientists from all over the world covering the major Pharma, Biotech and Clinical Research institutes will be participating.

Poster Presentations

- SUVN-I7016031: A Novel M1-receptor Positive Allosteric Modulator (M1-PAM) for the Treatment of Dementia Associated with Neurodegenerative Disorders(**Poster number: 154.08 / TT3**)
- Characterization of SUVN-7105012, a Potent and Selective Dual 5-HT1A and 5-HT2A Receptor Ligand That Exhibits Antipsychotic and Antidepressant Like Effects(**Poster number: 409.11 / YY27**)
- SUVN-N9503012: A 5-HT1A Receptor Partial Agonist for the Potential Treatment of Motor, Cognitive and Behavioral Dysfunction Associated with Parkinson's Disease(**Poster number: 449.16 / E57**)
- *In-vivo* Efficacy of SUVN-6206012 (P2X7R antagonist) on Chronic Constriction Injury Induced Neuropathic Pain in Two Different Species(**Poster number: 463.19 / T9**)
- Preclinical Characterization of the Potent M4 Muscarinic Receptor Positive Allosteric Modulator SUVN-L1305022(**Poster number: 522.05 / B20**)
- Masupirdine (SUVN-502): A Pure 5-HT6 Receptor Antagonist for the Treatment of Agitation/Aggression and Psychosis(**Poster number: 699.16 / E36**)

About Suven Life Sciences:

Suven Life Sciences is a clinical stage biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies. Suven has 4 clinical stage compounds, this Phase 3 masupirdine (SUVN-502) for treatment of agitation in patients with dementia of the Alzheimer's type, ongoing Phase 2 samelisant (SUVN-G3031) for sleep disorders (Narcolepsy), Phase 2 ready ropanicant (SUVN-911) for Major Depressive Disorder (MDD) and Phase 2 ready usmarapride (SUVN-D4010) for cognitive disorders. Apart from this Suven has 11 molecules in development pipeline. For more information please visit our website at <http://www.suven.com>

Disclaimer and Risk Statement:

Any information on Suven Intellectual Properties, Grant of Patents and Publications related to IP/Patents provided herewith is on as-is-where-is basis and all of the statements, expectations and assumptions, including expectations and assumptions, if any, contained in this update may be forward-looking that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Suven may not undertake to update any forward-looking statements that may be made from time to time.

Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7
Banjara Hills | Hyderabad – 500 034 | Telangana | India | CIN: L24110TG1989PLC009713
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com